SIGNiX and Exostar Partner to Deliver Secure, Compliant Digital Signature Solution to Life Science and Healthcare

Share Article

Researchers, Clinical Trial Participants, Physicians, and Others Can Access Cloud-Based Independent E-Signatures™ via the Exostar Life Sciences Identity Hub

SIGNiX’s Independent E-Signatures comply with global life sciences and healthcare industry standards and regulations, including the FDA’s 21 CFR Part 11, HIPAA, and the ESIGN Act.

SIGNiX’s Independent E-Signatures comply with global life sciences and healthcare industry standards and regulations, including the FDA’s 21 CFR Part 11, HIPAA, and the ESIGN Act.

Life science and healthcare organizations are demanding federated access to leading edge solutions, such as SIGNiX’s Independent E-Signatures, that enhance their productivity without sacrificing security or compliance

SIGNiX, the leading provider of Independent E-Signatures™, and Exostar an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, today announced a relationship that brings SIGNiX’s digital signature solution to Exostar’s life sciences and healthcare communities. With SIGNiX becoming Exostar’s latest Application Partner, organizations and individuals connected to Exostar's Life Sciences Identity Hub can leverage secure, single sign-on access to SIGNiX to quickly and easily sign business-critical and sensitive documents and forms online.

“Now, more than ever, parties in the life sciences and healthcare industries must be able to collaborate with one another securely, efficiently, effectively, and compliantly. At the same time, performance cannot be compromised by scale,” said Jay Jumper, SIGNiX’s CEO. “Exostar’s Life Sciences Identity Hub addresses these stringent requirements. By becoming a partner and connecting our application to the Identity Hub, we are adding value to Exostar’s compelling service offering.”

SIGNiX’s Independent E-Signatures comply with global life sciences and healthcare industry standards and regulations, including the FDA’s 21 CFR Part 11, HIPAA, and the ESIGN Act. They have also been approved by the SAFE-BioPharma Association, the non-profit organization that manages digital identity and signature standards for the pharmaceutical, biotech, and healthcare industries.

Researchers, investigators, patients, providers, and clinical trial participants benefit from signature process enforcement, faster document turnaround, reduced operating costs, and the flexibility to sign, send, and track documents from any device with an Internet connection. Because SIGNiX’s Independent E-Signatures rely on a fundamentally different technical approach, based entirely on secure digital signatures, Exostar community members will realize additional advantages, including:

•Ownership and Control – Users determine where documents reside, including on their own servers, rather than the vendor’s external server. Legal evidence is permanently embedded into the signed document so that signatures can be verified offline, anytime.

•Perpetual Validity – Because the legal evidence behind each signature is permanently embedded into the signed document and signatures adhere to international, published standards, they are valid virtually forever, as long as a digital copy of the signed document exists.

•Transparency – Users get immediate and complete access to the evidence of the signature’s validity through a comprehensive audit trail.

Exostar’s cloud-based Life Sciences Identity Hub supports a community of nearly 1,000 organizations and 20,000 individuals worldwide in their life sciences and healthcare endeavors. It serves not only as a platform that enables secure, internal and external collaboration, but also as a single sign-on entry point to a wealth of connected applications and solution provider portals that advance business objectives. Owners of connected assets define permission and user authentication strategies and rules, which are enforced by Exostar's Secure Access Manager. Coupled with extensive platform security and audit capabilities, application providers receive a secure connection experience, while sponsor organizations are assured their sensitive information and intellectual property are protected from compromise.

“Life sciences and healthcare organizations are demanding federated access to leading edge solutions, such as SIGNiX’s Independent E-Signatures, that enhance their productivity without sacrificing security or compliance,” said Daniel Pfeifle, Exostar’s Vice President of Sales and Marketing. “Our Partner Program is gaining momentum as Application Partners like SIGNiX recognize the vitally important role they can play in meeting this pressing need.”

About SIGNiX

SIGNiX, the most trusted name in independent e-signatures, makes signing documents online safe and secure with comprehensive legal evidence permanently embedded in each document to eliminate any dependence upon SIGNiX. The company’s cloud-based service uses patented technology to give businesses and organizations the most secure and legally defensible e-signatures available at a fraction of the cost of wet ink signatures. SIGNiX’s products help the world’s leading companies become more efficient, decrease risk and boost profits. For more information, visit http://www.signix.com.

About Exostar

Exostar powers secure business-to-business information sharing, collaboration and business process integration throughout the value chain. Exostar supports the complex trading needs of many of the world's largest companies in aerospace and defense, life sciences, and other industries. Exostar’s cloud-based identity assurance products and business applications reduce risk, improve agility and strengthen trading partner relationships and profitability for over 100,000 companies in 150 countries worldwide. The Exostar community includes market leaders such as AstraZeneca, BAE Systems, Bell Helicopter, The Boeing Company, Computer Sciences Corporation, Lockheed Martin Corp., Merck, Newport News Shipbuilding, Northrop Grumman, Raytheon Co. and Rolls-Royce. http://www.exostar.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Emily Maxie
SIGNiX
+1 423-305-7047
Email >
Visit website